Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease.

Religa, D; Czyzewski, K; Styczynska, M; Peplonska, B; Lokk, J; Chodakowska-Zebrowska, M; Stepien, K; Winblad, B; Barcikowska, M

Religa, D; Czyzewski, K; Styczynska, M; Peplonska, B; Lokk, J; Chodakowska-Zebrowska, M; Stepien, K; Winblad, B; Barcikowska, M.

Affiliation

Religa D; Department of Neurodegenerative Disorders, Medical Research Center, Polish Academy of Sciences, Warsaw, Poland. Dorota.Religa@ki.se

Neurosci Lett ; 404(1-2): 56-60, 2006 Aug 14.

Article in En | MEDLINE | ID: mdl-16787708

Subject(s)

Hyperhomocysteinemia/etiology; Methylenetetrahydrofolate Reductase (NADPH2)/genetics; Parkinson Disease/blood; Parkinson Disease/genetics; Polymorphism, Single Nucleotide; Adult; Aged; Aged, 80 and over; Folic Acid; Homocysteine/blood; Humans; Levodopa/therapeutic use; Middle Aged; Parkinson Disease/drug therapy; Reference Values; Vitamin B 12/blood

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Parkinson Disease / Hyperhomocysteinemia / Polymorphism, Single Nucleotide / Methylenetetrahydrofolate Reductase (NADPH2) Limits: Adult / Aged / Aged80 / Humans / Middle aged Language: En Journal: Neurosci Lett Year: 2006 Type: Article Affiliation country: Poland

Search on Google

XML

PubMed Links